The Reproductive Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Medicine (Baltimore). 2023 Mar 10;102(10):e33106. doi: 10.1097/MD.0000000000033106.
To evaluate the impact of Syndecan-1 (CD138) in proliferative-phase endometrium on pregnancy outcomes in fresh in vitro fertilization (IVF)/ intracytoplasmic sperm injection (ICSI) cycles. This retrospective cohort study contained 273 patients who underwent IVF/ICSI with fresh embryo transfer following an endometrial curettage from January 2020 to May 2022. Endometrial curettage was performed on all patients within 3 to 5 days following menstruation and endometrial tissue was acquired for detection of plasma cells by immunohistochemistry. Subsequent pregnancy outcomes of all cycles were traced and analyzed. A total of 149 patients became pregnant (i.e., pregnant group) in the fresh transfer IVF/ICSI cycles and 124 did not become pregnant (i.e., nonpregnant group). The number of CD138 + cells/ high-power field (HPF) of the nonpregnant group was significantly higher than the pregnant group (2.36 ± 4.24 vs 1.31 ± 3.41, P = .008). The cut off value of CD138 + cells/HPF was 2 by receiver operating characteristic curve analysis, with an area under the receiver operating characteristic curve of 0.572. Compared with the negative group (i.e., CD138 + cells/HPF < 2, n = 204), the positive group (i.e., CD138 + cells/HPF ≥ 2, n = 69) had a significantly lower clinical pregnancy rate (71.8% vs 40.6%, P < .001). The clinical pregnancy rate revealed a gradually decreasing trend with the increase in CD138 + cells. Proliferative-phase endometrial CD138 + cells may be an adverse indicator for pregnancy outcomes in fresh IVF/ICSI cycles, with a certain value in predicting non-pregnancy. Pregnancy outcome was poor when CD138 + cells/HPF ≥ 2 in the endometrium and may worsen with the increase in CD138 + cells.
评估增殖期子宫内膜中硫酸乙酰肝素蛋白聚糖 1（CD138）对新鲜体外受精（IVF）/卵胞浆内单精子注射（ICSI）周期妊娠结局的影响。
本回顾性队列研究纳入了 2020 年 1 月至 2022 年 5 月期间因子宫内膜刮除术而行新鲜胚胎移植的 273 例 IVF/ICSI 患者。所有患者均在月经后 3-5 天行子宫内膜刮除术，并通过免疫组织化学检测浆细胞获取子宫内膜组织。追踪并分析所有周期的后续妊娠结局。在新鲜移植 IVF/ICSI 周期中，有 149 例患者妊娠（即妊娠组），124 例患者未妊娠（即未妊娠组）。未妊娠组的 CD138+细胞/高倍视野（HPF）数量明显高于妊娠组（2.36±4.24 比 1.31±3.41，P=0.008）。通过受试者工作特征曲线分析，CD138+细胞/HPF 的截断值为 2，受试者工作特征曲线下面积为 0.572。与阴性组（即 CD138+细胞/HPF<2，n=204）相比，阳性组（即 CD138+细胞/HPF≥2，n=69）的临床妊娠率显著降低（71.8%比 40.6%，P<0.001）。临床妊娠率随 CD138+细胞的增加呈逐渐下降趋势。增殖期子宫内膜 CD138+细胞可能是新鲜 IVF/ICSI 周期妊娠结局的不良指标，对预测妊娠结局有一定价值。当子宫内膜中 CD138+细胞/HPF≥2 时，妊娠结局较差，且随着 CD138+细胞的增加而恶化。
